Celldex Therapeutics (CLDX) Stock Price, Quote & News

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhi...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 200 7500

Fax: 908 454 1911

Website: www.celldex.com

Address:

Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

Timefortendies77 Jul. 31 at 12:17 AM

$CLDX The only downside here is it is mostly owned by institutions so the option market is a ghost town with crap prices.

0 · Reply

Steve1545 Jul. 30 at 9:48 PM

$CLDX

0 · Reply

Cache_Money Jul. 30 at 4:04 PM

$CLDX Expecting to see continued momentum in anticipation of the phase 3 KIT antibody readout for CSU

0 · Reply

Unburdened Jul. 29 at 8:10 PM

$CLDX Great day. Still think we are at $40 by the end of August.

1 · Reply

lucabrix Jul. 29 at 7:36 PM

$CLDX Reply!

0 · Reply

anachartanalyst Jul. 29 at 5:02 PM

$CLDX https://anachart.com/wp-content/uploads/2026/07/1785344523_soc-img.jpg

0 · Reply

Quantumup Jul. 29 at 12:11 PM

Wells Fargo⬆️ $CLDX's PT to $72 from $48,⬆️barzolvolimab's estimates, and reiterated an Overweight rating. $NVS - $RHHBY SNY REGN Wells Fargo said -- While the St is modeling a high probability of success (PoS) for barzolvolimab's Ph3 in chronic spontaneous urticaria (CSU), it under-appreciates its commercial opportunity and potential early-line utilization due to overstated concerns around monitoring requirements and safety.

0 · Reply

CH_Expat Jul. 28 at 2:00 PM

Okay guys, new prime candidates for starters (at lower valuations of course) are $NAMS -$NRIX - $IMTX - $CLDX and CELC. Than we have some others, but far away from my entry points. IDYA and MLYS unchanged.

4 · Reply

Unburdened Jul. 25 at 1:33 PM

$CLDX Like where this ended considering the news this week. Rallied back. Thinking this will march towards $40 by end of August.

0 · Reply

Timefortendies77 Jul. 23 at 2:42 PM

$CLDX Back to the 35s!

0 · Reply

Celldex price target raised to $72 from $48 at Wells Fargo

2026-07-22T11:35:20.000Z - 9 days ago

Celldex price target lowered to $61 from $67 at Cantor Fitzgerald

2026-07-22T11:12:10.000Z - 9 days ago

Celldex price target lowered to $48 from $54 at Wells Fargo

2026-07-22T10:50:11.000Z - 9 days ago

Celldex price target lowered to $40 from $44 at Morgan Stanley

2026-07-22T10:45:30.000Z - 9 days ago

Celldex price target lowered to $60 from $62 at Canaccord

2026-07-22T10:05:17.000Z - 9 days ago

Celldex price target lowered to $70 from $78 at Leerink

Jul 21, 2026, 4:44 PM EDT - 10 days ago

Celldex to stop skin disease study after trial setback

Jul 21, 2026, 4:30 PM EDT - 10 days ago

Celldex Therapeutics Transcript: Study result

Jul 21, 2026, 4:30 PM EDT - 10 days ago

Celldex Therapeutics Press release: Study result

Jul 21, 2026, 4:30 PM EDT - 10 days ago

Celldex Therapeutics Slides: Study result

2026-07-21T20:11:22.000Z - 10 days ago

Celldex reports barzolvolimab study did not meet primary, secondary endpoints

Jul 21, 2026, 4:01 PM EDT - 10 days ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

2026-07-20T11:10:53.000Z - 11 days ago

Celldex price target raised to $100 from $90 at Guggenheim

2026-07-15T20:11:17.000Z - 16 days ago

Celldex CFO Sam Martin to retire in 2027

Jul 15, 2026, 4:01 PM EDT - 16 days ago

Celldex Announces Planned Transition of Chief Financial Officer

Jun 25, 2026, 9:00 AM EDT - 5 weeks ago

Celldex Therapeutics Transcript: AGM 2026

2026-06-14T20:55:30.000Z - 6 weeks ago

Celldex presents long-term results from Phase 2 study of barzolvolimab

2026-06-14T20:50:28.000Z - 6 weeks ago

Celldex presents first-in-human results for CDX-622

Jun 14, 2026, 10:21 AM EDT - 6 weeks ago

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Jun 14, 2026, 5:15 AM EDT - 6 weeks ago

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Jun 10, 2026, 4:01 PM EDT - 7 weeks ago

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

2026-06-10T12:20:05.000Z - 7 weeks ago

Celldex price target raised to $45 from $38 at UBS

May 28, 2026, 7:00 AM EDT - 2 months ago

Celldex Therapeutics Slides: Corporate presentation

2026-05-13T11:08:49.000Z - 2 months ago

Celldex price target raised to $54 from $38 at Wells Fargo

2026-05-08T18:28:10.000Z - 3 months ago

Celldex price target raised to $38 from $34 at Goldman Sachs

2026-05-08T10:20:55.000Z - 3 months ago

Celldex price target raised to $48 from $45 at Barclays

2026-05-07T21:42:55.000Z - 3 months ago

Celldex sees funds sufficient to fund current planned operations through 2028

May 7, 2026, 4:01 PM EDT - 3 months ago

Celldex Reports First Quarter Financial Results and Provides Corporate Update

May 7, 2026, 4:00 PM EDT - 3 months ago

Celldex Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 3 months ago

Celldex Therapeutics Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Celldex Therapeutics Proxy statement: Proxy filing

2026-04-20T14:19:17.000Z - 3 months ago

A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)

Apr 14, 2026, 3:30 PM EDT - 3 months ago

Celldex Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Apr 13, 2026, 4:01 PM EDT - 3 months ago

Celldex to Present at Upcoming Investor Conference

Apr 6, 2026, 10:53 AM EDT - 4 months ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 1, 2026, 9:48 PM EDT - 4 months ago

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Apr 1, 2026, 4:01 PM EDT - 4 months ago

Celldex Announces Proposed Public Offering of Common Stock

Mar 27, 2026, 10:30 AM EDT - 4 months ago

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

Mar 10, 2026, 3:40 PM EDT - 5 months ago

Celldex Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 9:10 AM EST - 5 months ago

Celldex Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 2:45 PM EST - 5 months ago

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Feb 25, 2026, 4:01 PM EST - 5 months ago

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Feb 25, 2026, 4:00 PM EST - 5 months ago

Celldex Therapeutics Annual report: Q4 2025

Feb 25, 2026, 4:00 PM EST - 5 months ago

Celldex Therapeutics Earnings release: Q4 2025

Feb 25, 2026, 7:01 AM EST - 5 months ago

Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Feb 23, 2026, 8:01 AM EST - 5 months ago

Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile

Feb 11, 2026, 3:30 PM EST - 6 months ago

Celldex Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 8:01 AM EST - 6 months ago

Celldex to Present at Upcoming Investor Conferences

Dec 9, 2025, 8:01 AM EST - 8 months ago

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Dec 2, 2025, 3:00 PM EST - 8 months ago

Celldex Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 13, 2025, 9:30 AM EST - 9 months ago

Celldex Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 10:00 AM EST - 9 months ago

Celldex Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:01 AM EST - 9 months ago

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Nov 10, 2025, 12:00 AM EST - 9 months ago

Celldex Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 12:00 AM EST - 9 months ago

Celldex Therapeutics Earnings release: Q3 2025

Sep 17, 2025, 5:11 AM EDT - 11 months ago

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Sep 9, 2025, 3:20 PM EDT - 11 months ago

Celldex Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 9:01 AM EDT - 11 months ago

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 19, 2025, 4:30 PM EDT - 1 year ago

Celldex Therapeutics Transcript: Study Update

Aug 19, 2025, 4:30 PM EDT - 1 year ago

Celldex Therapeutics Press release: Study Update

Aug 19, 2025, 4:01 PM EDT - 1 year ago

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Celldex Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Celldex Therapeutics Quarterly report: Q2 2025

Jun 14, 2025, 10:48 AM EDT - 1 year ago

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Jun 12, 2025, 6:01 PM EDT - 1 year ago

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Jun 12, 2025, 6:00 PM EDT - 1 year ago

Celldex Therapeutics Transcript: Status Update

Jun 12, 2025, 6:00 PM EDT - 1 year ago

Celldex Therapeutics Slides: Status Update

Jun 10, 2025, 4:01 PM EDT - 1 year ago

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Jun 6, 2025, 8:01 AM EDT - 1 year ago

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

May 8, 2025, 4:01 PM EDT - 1 year ago

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 12:00 AM EDT - 1 year ago

Celldex Therapeutics Earnings release: Q1 2025

May 8, 2025, 12:00 AM EDT - 1 year ago

Celldex Therapeutics Quarterly report: Q1 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Proxy statement: Proxy Filing

Mar 11, 2025, 1:00 PM EDT - 1 year ago

Celldex Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 1:50 PM EST - 1 year ago

Celldex Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

Mar 3, 2025, 8:01 AM EST - 1 year ago

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Mar 1, 2025, 12:45 PM EST - 1 year ago

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Feb 27, 2025, 4:01 PM EST - 1 year ago

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 9:30 AM EST - 1 year ago

Celldex Therapeutics Annual report: Q4 2024

Feb 27, 2025, 9:30 AM EST - 1 year ago

Celldex Therapeutics Earnings release: Q4 2024

Dec 19, 2024, 8:01 AM EST - 1 year ago

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Dec 3, 2024, 4:15 PM EST - 1 year ago

Celldex Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 20, 2024, 8:01 AM EST - 1 year ago

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Nov 12, 2024, 4:00 PM EST - 1 year ago

Celldex Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 4:01 PM EST - 1 year ago

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 6:00 PM EST - 1 year ago

Celldex Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Celldex Therapeutics Earnings release: Q3 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Transcript: Status Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Press release: Status Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Celldex Therapeutics Slides: Status Update

Oct 26, 2024, 5:43 PM EDT - 1 year ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Oct 25, 2024, 8:01 AM EDT - 1 year ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

Oct 4, 2024, 7:00 AM EDT - 1 year ago

Celldex Therapeutics Slides: Corporate Presentation

Sep 25, 2024, 10:45 AM EDT - 2 years ago

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Sep 20, 2024, 10:00 AM EDT - 2 years ago

Celldex Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Sep 17, 2024, 8:35 AM EDT - 2 years ago

Celldex Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 16, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Aug 8, 2024, 4:01 PM EDT - 2 years ago

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Celldex Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Celldex Therapeutics Earnings release: Q2 2024

Jul 29, 2024, 4:30 PM EDT - 2 years ago

Celldex Therapeutics Transcript: Study Result

Jul 29, 2024, 4:30 PM EDT - 2 years ago

Celldex Therapeutics Press release: Study Result

Jul 29, 2024, 4:01 PM EDT - 2 years ago

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Jul 16, 2024, 8:01 AM EDT - 2 years ago

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Jun 4, 2024, 4:01 PM EDT - 2 years ago

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2024, 9:01 AM EDT - 2 years ago

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

May 15, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

May 6, 2024, 4:01 PM EDT - 2 years ago

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 7:00 AM EDT - 2 years ago

Celldex Therapeutics Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Celldex Therapeutics Earnings release: Q1 2024

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Celldex Therapeutics Proxy statement: Proxy Filing

Apr 17, 2024, 8:01 AM EDT - 2 years ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Mar 8, 2024, 7:00 AM EST - 2 years ago

Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 10:30 AM EST - 2 years ago

Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Timefortendies77 Jul. 31 at 12:17 AM

$CLDX The only downside here is it is mostly owned by institutions so the option market is a ghost town with crap prices.

0 · Reply

Steve1545 Jul. 30 at 9:48 PM

$CLDX

0 · Reply

Cache_Money Jul. 30 at 4:04 PM

$CLDX Expecting to see continued momentum in anticipation of the phase 3 KIT antibody readout for CSU

0 · Reply

Unburdened Jul. 29 at 8:10 PM

$CLDX Great day. Still think we are at $40 by the end of August.

1 · Reply

lucabrix Jul. 29 at 7:36 PM

$CLDX Reply!

0 · Reply

anachartanalyst Jul. 29 at 5:02 PM

$CLDX https://anachart.com/wp-content/uploads/2026/07/1785344523_soc-img.jpg

0 · Reply

Quantumup Jul. 29 at 12:11 PM

0 · Reply

CH_Expat Jul. 28 at 2:00 PM

4 · Reply

Unburdened Jul. 25 at 1:33 PM

$CLDX Like where this ended considering the news this week. Rallied back. Thinking this will march towards $40 by end of August.

0 · Reply

Timefortendies77 Jul. 23 at 2:42 PM

$CLDX Back to the 35s!

0 · Reply

lucabrix Jul. 22 at 7:18 PM

$CLDX Nice recover!

0 · Reply

Timefortendies77 Jul. 22 at 3:26 PM

$CLDX What do you all think this will do with positive CSU?

1 · Reply

Timefortendies77 Jul. 22 at 2:07 PM

$CLDX Coming back to 35 was nice, but I guess it wants to trim a bit before stabalizing. Updates won't come for 2-3 months now.

0 · Reply

CH_Expat Jul. 22 at 2:02 PM

$CLDX Was hoping for more panic selloff after the nothing burger.

0 · Reply

Quantumup Jul. 22 at 12:18 PM

Canaccord Genuity y'day⬇️ $CLDX to $60 (was $60) and reiterated Buy $RHHBY $SNY - REGN NVS Here's what Canaccord Genuity said in its note to investors: https://x.com/Quantumup1/status/2079903712420512187?s=20

1 · Reply

FactsPlease99 Jul. 22 at 11:57 AM

$CLDX Well I asked AI and got my answer. Let’s hope Anthony can get just one drug over the finish line or the company is finished. Not sure I have seen a Biotech with this many failures? Great fuel for shorts Celldex Therapeutics has had 5 major clinical trial failures that resulted in the complete discontinuation of those specific drug programs. Barzolvolimab (in Prurigo Nodularis): Halted in July 2026 after the antibody failed to show meaningful improvements in itch or skin lesions Barzolvolimab (in Eosinophilic Esophagitis): Discontinued in 2025 despite hitting its primary endpoint, as the depletion of mast cells did not translate to meaningful clinical improvements for patients. Glembatumumab vedotin (gpNMB program): Axed in 2018 across all indications after a Phase 2b trial (METRIC study) failed to improve progression-free survival. Rintega (rindopepimut): Halted in 2016 when a Phase 3 study for glioblastoma Varlilumab & CDX-301: Immunotherapy

3 · Reply

FactsPlease99 Jul. 22 at 11:45 AM

$CLDX brings back memories of the failed past trials. Some things just never change at Celldex.

0 · Reply

Dont_Forget_The_Dates Jul. 22 at 11:04 AM

$CLDX Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44

1 · Reply

StocktwitsNews Jul. 21 at 10:52 PM

CLDX Stock Down 10% After-Hours — What’s Driving The Selloff? $CLDX $XBI $IWM https://stocktwits.com/news/equity/markets/cldx-stock-down-10-after-hours-what-s-driving-the-selloff/cZZSoHgR7wG

0 · Reply

Timefortendies77 Jul. 21 at 9:54 PM

$CLDX They were encouraged by the safety from the trial--going into the Phase 3 trials so that is good-onward and upward--CSU sept/oct!

0 · Reply

notreload_ai Jul. 21 at 9:39 PM

$CLDX discontinues barzolvolimab development in prurigo nodularis after its Phase 2 study failed to meet the primary endpoint and key secondary endpoints. https://notreload.xyz/xy/celldex-discontinues-barzolvolimab-for-prurigo-nodularis/

0 · Reply

CH_Expat Jul. 21 at 8:50 PM

$CLDX How likely is another fail for CSU P3?

1 · Reply

Market Cap	3.02B
Revenue (ttm)	1.55M
Net Income (ttm)	-258.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-16,694.19%
Debt to Equity Ratio	0.00

Volume	875,700
Avg Vol	1,053,708
Day's Range	N/A - N/A
Shares Out	78.49M
Stochastic %K	89%
Beta	0.90
Analysts	Strong Sell
Price Target	$57.80